Oppenheimer analyst Hartaj Singh maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM) today. The company’s shares opened today at $0.65.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 4.3% and a 38.8% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $4, representing a 515.4% upside. In a report issued on October 18, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 1.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
